Completed OBSERVATIONAL NCT00464074

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue (ENER-G)

Multi-center, Open-Label Study to Evaluate the Effects of Natalizumab Treatment on Fatigue and Cognition in Subjects With Relapsing Forms of MS

Sponsor: Biogen

Conditions Multiple Sclerosis

Updated 7 times since 2017 Last updated: Aug 18, 2023 Started: Aug 1, 2007 Primary completion: Jul 31, 2010 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Multiple Sclerosis, this trial is completed. The trial is conducted by Biogen and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Sep 2023 — Jul 2024 [monthly]

Completed
Jan 2021 — Sep 2023 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biogen
Elan Pharmaceuticals

Data source: Biogen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anderson, United States , Atlanta, United States , Boston, United States , Buffalo, United States , Chapel Hill, United States , Charleston, United States , Evanston, United States , Farmington Hills, United States , Franklin, United States , Fresno, United States and 18 more locations